Skip to main content

Table 5 Comparing sedative drug use and cumulative administered dose among patients with and without delayed intracranial conduction time

From: Early impairment of intracranial conduction time predicts mortality in deeply sedated critically ill patients: a prospective observational pilot study

Variables All patients SSEP’s P14–N20 (ICCT) BAEP’s III–V (IPCT)
Delayed Non delayed *p value Delayed Non delayed *p value
Number of patients—n (%) 86 (100) 39 (45) 47 (55)   15 (17) 71 (83)  
RASS—median (IQR) −5 (−5 to −4.2) −5 (−5 to −5) −5 (−5 to −4) 0.003 −5 (−5 to −4) −5 (−5 to −5) 0.45
Body temperature (°C)—mean (SD) 36. (1.0) 36.7 (1.0) 36.4 (0.9) 0.10 36.5 (1.1) 36.6 (1.0) 0.67
Sedative drugs used
 Midazolam—n (%) 79 (92) 36 (42) 43 (50) 0.89 14 (18) 65 (82) 0.82
 Sufentanil—n (%) 79 (92) 37 (43) 42 (49) 0.36 15 (19) 64 (81) 0.21
 Propofol—n (%) 9 (10) 2 (2) 7 (8) 0.14 1 (11) 8 (89) 0.60
Sedative drugs’ cumulative doses
 Midazolam (mg/kg)—median (IQR) 5 (5 to 8) 5 (5 to 9) 5 (5 to 8) 0.74 5 (4.2 to 9) 5 (5 to 8) 0.54
 Sufentanil (µg/kg)—median (IQR) 20 (10 to 30) 20 (10 to 30) 20 (10 to 30) 0.70 20 (10 to 25) 20 (10 to 30) 0.63
 Propofol (mg/kg)—median (IQR) 10 (0 to 40) 3 (1.5 to 6) 20 (1.5 to 85) 0.22 3 (3 to 3) 15 (0 to 55) 0.40
 Abnormal brain imaging—n (%) 34/59 (58) 18/34 (53) 16/34 (47) 0.08 5/34 (15) 29/34 (85) 0.46
 Focal brain injury—n (%) 11 (32) 6 (55) 5 (45) 0.96 1 (9) 10 (91) 0.72
 Diffuse brain injury—n (%) 23 (68) 12 (52) 11 (48) 0.78 4 (17) 19 (83) 0.66
  1. * Mann–Whitney test